← All trials
NCT01425307
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2011
- Primary completion
- Mar 1, 2015
- Completion date
- Nov 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 159
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of CincinnatiLead sponsor
- University of CincinnatiOverall official - principal investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Columbia UniversityCollaborator
- University of South AlabamaCollaborator
- University of MiamiCollaborator
- Wayne State UniversityCollaborator
- Duke UniversityCollaborator
- East Carolina UniversityCollaborator
- St. Jude Children's HospitalCollaborator
- Thomas Jefferson UniversityCollaborator
- University of MinnesotaCollaborator
- Old Dominion UniversityCollaborator
- University of PennsylvaniaCollaborator
- Emory UniversityCollaborator
- Children's National Medical CenterCollaborator
- Baylor UniversityCollaborator
- University of TorontoCollaborator
- Case Western Reserve UniversityCollaborator
- Medical University of South CarolinaCollaborator
- State University of New York, BrooklynCollaborator
- Steven & Alexandra Cohen Children's Medical Center, New YorkCollaborator
- Northwestern UniversityCollaborator
- Harvard UniversityCollaborator
- University of Alabama, BirminghamCollaborator
- University of MississippiCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.